SG-293

Drug

Related News

Sana Biotechnology names Brian Piper CFO as it advances SC451 and SG293

Apr 14, 2026

Sana Biotechnology named Brian Piper executive vice president and CFO as it advanced SC451 and SG293. The company reported a fourth-quarter loss of $59 million and cash of $138 million.

Sana Biotechnology Appoints Brian Piper as CFO and Executive Vice President

Feb 17, 2026

Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer on February 17, 2026. Piper brings over 25 years of biopharmaceutical financial expertise to the cell and gene therapy company.